These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
442 related articles for article (PubMed ID: 33738267)
21. The antibacterial activity of E. coli bacteriophage lysin lysep3 is enhanced by fusing the Bacillus amyloliquefaciens bacteriophage endolysin binding domain D8 to the C-terminal region. Wang S; Gu J; Lv M; Guo Z; Yan G; Yu L; Du C; Feng X; Han W; Sun C; Lei L J Microbiol; 2017 May; 55(5):403-408. PubMed ID: 28124780 [TBL] [Abstract][Full Text] [Related]
22. Design SMAP29-LysPA26 as a Highly Efficient Artilysin against Pseudomonas aeruginosa with Bactericidal and Antibiofilm Activity. Wang T; Zheng Y; Dai J; Zhou J; Yu R; Zhang C Microbiol Spectr; 2021 Dec; 9(3):e0054621. PubMed ID: 34878337 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii. Defraine V; Schuermans J; Grymonprez B; Govers SK; Aertsen A; Fauvart M; Michiels J; Lavigne R; Briers Y Antimicrob Agents Chemother; 2016 Jun; 60(6):3480-8. PubMed ID: 27021321 [TBL] [Abstract][Full Text] [Related]
24. Antibacterial properties of Acinetobacter baumannii phage Abp1 endolysin (PlyAB1). Huang G; Shen X; Gong Y; Dong Z; Zhao X; Shen W; Wang J; Hu F; Peng Y BMC Infect Dis; 2014 Dec; 14():681. PubMed ID: 25495514 [TBL] [Abstract][Full Text] [Related]
25. The characteristic and potential therapeutic effect of isolated multidrug-resistant Acinetobacter baumannii lytic phage. Sisakhtpour B; Mirzaei A; Karbasizadeh V; Hosseini N; Shabani M; Moghim S Ann Clin Microbiol Antimicrob; 2022 Jan; 21(1):1. PubMed ID: 34996464 [TBL] [Abstract][Full Text] [Related]
26. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators. Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770 [TBL] [Abstract][Full Text] [Related]
27. [Analysis of distribution and drug resistance of pathogens of burn patients during 9 years]. Dou Y; Zhang Q Zhonghua Shao Shang Za Zhi; 2018 Mar; 34(3):153-159. PubMed ID: 29609277 [No Abstract] [Full Text] [Related]
28. In Vitro Study of Bacteriophage AB3 Endolysin LysAB3 Activity Against Acinetobacter baumannii Biofilm and Biofilm-Bound A. baumannii. Zhang J; Xu LL; Gan D; Zhang X Clin Lab; 2018 Jun; 64(6):1021-1030. PubMed ID: 29945306 [TBL] [Abstract][Full Text] [Related]
29. Lysin LysMK34 of Abdelkader K; Gutiérrez D; Grimon D; Ruas-Madiedo P; Lood C; Lavigne R; Safaan A; Khairalla AS; Gaber Y; Dishisha T; Briers Y Appl Environ Microbiol; 2020 Sep; 86(19):. PubMed ID: 32709718 [TBL] [Abstract][Full Text] [Related]
30. Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens. Pollini S; Brunetti J; Sennati S; Rossolini GM; Bracci L; Pini A; Falciani C J Pept Sci; 2017 Apr; 23(4):329-333. PubMed ID: 28176481 [TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. Blasco L; Ambroa A; Trastoy R; Bleriot I; Moscoso M; Fernández-Garcia L; Perez-Nadales E; Fernández-Cuenca F; Torre-Cisneros J; Oteo-Iglesias J; Oliver A; Canton R; Kidd T; Navarro F; Miró E; Pascual A; Bou G; Martínez-Martínez L; Tomas M Sci Rep; 2020 Apr; 10(1):7163. PubMed ID: 32346029 [TBL] [Abstract][Full Text] [Related]
33. Characterization of a novel bacteriophage endolysin (LysAB1245) with extended lytic activity against distinct capsular types associated with Acinetobacter baumannii resistance. Soontarach R; Srimanote P; Arechanajan B; Nakkaew A; Voravuthikunchai SP; Chusri S PLoS One; 2024; 19(1):e0296453. PubMed ID: 38165983 [TBL] [Abstract][Full Text] [Related]
34. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients]. Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922 [No Abstract] [Full Text] [Related]
35. Evaluation of the in vitro colistin susceptibility of Pseudomonas aeruginosa and Acinetobacter baumannii strains at a tertiary care centre in Western Turkey. Ece G; Samlioglu P; Atalay S; Kose S Infez Med; 2014 Mar; 22(1):36-40. PubMed ID: 24651089 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of the rapid ResaPolymyxin Jung H; Pitout JDD; Mitton BC; Strydom KA; Kingsburgh C; Coetzee J; Ehlers MM; Kock M J Med Microbiol; 2021 Jun; 70(6):. PubMed ID: 34165418 [No Abstract] [Full Text] [Related]
37. Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria. Khan FM; Rasheed F; Yang Y; Liu B; Zhang R Front Pharmacol; 2024; 15():1385261. PubMed ID: 38831886 [TBL] [Abstract][Full Text] [Related]
38. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria. Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003 [TBL] [Abstract][Full Text] [Related]
39. Fluorescence High-Throughput Screening for Inhibitors of TonB Action. Nairn BL; Eliasson OS; Hyder DR; Long NJ; Majumdar A; Chakravorty S; McDonald P; Roy A; Newton SM; Klebba PE J Bacteriol; 2017 May; 199(10):. PubMed ID: 28242720 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]